Murat Tunaboylu

Murat Tunaboylu is a Turkish entrepreneur and biotechnology leader whose career has spanned software engineering, bioinformatics, and life science automation. He holds a Bachelor's degree in Electrical Engineering from Yildiz Technical University in Istanbul and a Master's in Computer Engineering from Bahçeşehir University. His early career included roles in software engineering at Susquehanna International Group and automating DNA synthesis workflows at Thermo Fisher Scientific, where he built deep expertise in lab automation and computational biology across more than 15 years of industry experience.

In 2017, Tunaboylu co-founded Antiverse in Cardiff, Wales, with the vision of using machine learning to solve one of drug discovery's most intractable challenges: designing antibodies for difficult-to-drug targets such as G protein-coupled receptors (GPCRs) and ion channels. As CEO, he has built the company into a leading techbio platform that integrates generative AI with in-house wet lab capabilities, compressing the antibody discovery timeline from years to under six months. Antiverse's 'target-specific library' approach uses structural and sequence data to achieve predictive accuracy far beyond conventional methods.

Under Tunaboylu's leadership, Antiverse has raised over $20 million in total funding, including a £3.5 million seed extension in 2024 led by i&i Biotech Fund and Kadmos Capital, and a $9.3 million Series A in 2025. The company has entered major partnerships with pharma players including Nxera Pharma, and a research agreement with the Cystic Fibrosis Foundation, positioning Antiverse as a global force in next-generation antibody therapeutics.